Big Tobacco Is Betting $2 Billion on This Pot Stock

Tobacco giant Altria Group (NYSE:MO) is betting billions that pot producer Cronos Group Inc (TSX:CRON)(NASDAQ:CRON) will produce big gains.

| More on:
edit Jars of marijuana

Image source: Getty Images

Altria Group (NYSE:MO) is one of the largest tobacco producers in the world. Its size is truly remarkable.

Last quarter, despite the onset of the COVID-19 pandemic, the company generated more than $5 billion in sales. It also produced a quarterly profit of nearly $2 billion, up 38% year over year. Those profits help service an 8.6% dividend.

If you had invested $10,000 in this stock when it first went public, you’d have more than $1 million today. And that’s not including any dividends.

But Altria isn’t done yet. It wants to recreate the success it’s had in tobacco with other markets, namely cannabis. That’s why it invested roughly $2 billion for a 45% stake in a leading pot stock. It’s an exclusive partnership. If Altria capitalizes on cannabis, it’ll be through this stock.

There’s good reason to believe this will be a long-term winner. Yet due to the coronavirus correction, most pot stocks trade at ridiculously low valuations. This company is no different.

If you want to profit from pot by betting alongside one of the most successful tobacco companies in history, this is your chance.

A rare opportunity

Cronos Group Inc (TSX:CRON)(NASDAQ:CRON) is a giant in the cannabis world with a $2.9 billion market cap. But that’s a little misleading given that it has around $1.8 billion in cash. That means the true valuation of the business, when stripping out the cash on the balance sheet, is only around $1.1 billion. That’s crazy.

Consider Altria’s size. It’s currently worth nearly $100 billion. And that’s after a steep drop due to the coronavirus correction.

If Cronos can even achieve that size, there will be 100 times upside. There’s actually precedence to this. Since 1980, Altria stock has risen almost exactly 100 times in value.

Altria clearly hopes to replicate its success in tobacco with cannabis. Will it succeed? At this valuation, it’s certainly worth betting on. That’s because there’s a lot in common between these two companies. More than the market appreciates.

Trust big tobacco

If you want to bet on pot stocks, bet on the Altria-Cronos partnership. The choice is clear.

The most important thing for any pot stock to do is avoid commoditization. Tobacco, at the end of the day, is a pure commodity. Yet Altria gets customers to pay a hefty mark-up for its products. That’s because it’s an expert at branding. Its brand portfolio, which includes icons like Marlboro, commands 50% of the U.S. cigarette market.

Thus far, few cannabis companies have cracked the code of branding. Can you name a single marijuana brand? I didn’t think so. But I’m sure you can think of a tobacco brand or two, even if you don’t smoke.

Pot stocks that can’t avoid commoditization will lose. It’s like betting on a company that sells tomatoes or carrots. The market doesn’t value Coca-Cola Co at $200 billion because it sells water and sugar. The company has a gargantuan market cap because it sells a global brand.

Altria has a proven track record of branding regulated products like tobacco. With billions in the bank and direct assistance from Altria, I’m betting Cronos will crack the code for cannabis.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ryan Vanzo has no position in any stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »